test | GS Interactive

SNS-301

ASPH; HPV- specific E6/E7

1st Line Head & Neck Cancer in combination with pembrolizumab

PD-1 blockade has been approved for several years in the treatment of advanced SCCHN after platinum-containing chemotherapy, but the objective response rate has been reported to be modest at 13% to 18% with progression-free survival (PFS) of two months and overall survival (OS) of eight months.
The addition of SNS-301 has the potential to enhance PD-1 blockade activity.
We also intend to use an ImmunoPhage cocktail targeting the E6/E7 antigens of HPV, in combination with SNS-301, in HPV-positive patients in our ongoing trial of SNS-301.

Head & Neck Cancer Neoadjuvant in combination with durvalumab

We will evaluate the safety and efficacy of SNS-301 in combination with durvalumab for patients with locally advanced, resectable SCCHN in the neoadjuvant setting.

SNS-401

Cocktail with MCPyV

Merkel Cell Carcinoma

First custom MCC vaccine consisting of Merkel Cell Polyoma Virus (MCPyV) epitopes together with other patient-specific antigens.
MCC is a rare but highly aggressive neuroendocrine carcinoma of the skin in which MCPyV infection and chronic exposure to ultraviolet radiation are key risk factors.
Although systemic PD-1/PD-L1 inhibition therapy is associated with a high overall response rate, prolonged durable responses, and good tolerability in advanced-stage MCC, refractory PD-1/PD-L1 inhibitor disease remains a significant unmet medical need with an aggressive clinical course.

SNS-VISTA

VISTA

Solid Tumors

VISTA is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils, monocytes, macrophages, basophils, and dendritic cells.
VISTA blockade appears to dramatically modulate the tumor microenvironment toward a state that favors an immune system response, resulting in improved T cell effector function and anti-tumor activity.

Nanobodies & Antibodies

Various

Discovery & validation of multiple antibodies & nanobodies utilizing ImmunoPhage platform

Proprietary nanobodies, derived from alpacas, are antibody-like structures that consist of a single monomeric variable domain located on the heavy chain.
We are developing nanobodies targeted to immune checkpoints and other immune-stimulatory molecules that can be packaged into the phage as immunomodulatory payloads to enhance immunogenicity.